22157.jpg
Smoking Cessation and Nicotine Deaddiction Landscape Report 2024: Therapeutic Assessment of Novel Drug Candidates, Emerging Drugs and the Route to Commercialization
April 12, 2024 10:04 ET | Research and Markets
Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The global commitment...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
April 11, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
March 20, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Transparency Market Research
Smoking Cessation and Nicotine De-Addiction Market to Reach USD 27.84 billion by 2031, at a CAGR of 10.2% - Transparency Market Research, Inc.
March 11, 2024 07:30 ET | Transparency Market Research
Wilmington, Delaware, United States, March 11, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global smoking cessation and nicotine de-addiction market is estimated to flourish at a...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
March 06, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
February 29, 2024 08:01 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
February 29, 2024 08:00 ET | Achieve Life Sciences
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds to conduct clinical development of...
22157.jpg
Nicotine Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast to 2030
February 28, 2024 12:18 ET | Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "Nicotine Replacement Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
Global Substance Abuse Disorder Treatment Market
Global Substance Abuse Disorder Treatment Research Analysis Report 2024: Public and Private Entities Join Forces to Tackle Substance Abuse Epidemic - Forecasts to 2034
January 31, 2024 09:44 ET | Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Disorder Treatment Market Analysis & Forecast 2024-2034: Market By Treatment; By End-user; and By Region" report has been...
22157.jpg
Smoking Cessation Aids Market in the US Undergoes Major Shift Towards Oral NRT Options
January 28, 2024 19:43 ET | Research and Markets
Dublin, Jan. 28, 2024 (GLOBE NEWSWIRE) -- The "NRT Smoking Cessation Aids in the US" report has been added to ResearchAndMarkets.com's offering.NRT patches is set to continue to witness steep...